Last reviewed · How we verify

doxorubicin, ifosfamide, cisplatin

Gustave Roussy, Cancer Campus, Grand Paris · Phase 3 active Small molecule

doxorubicin, ifosfamide, cisplatin is a anthracycline antibiotic, alkylating agent, platinum-based alkylating agent Small molecule drug developed by Gustave Roussy, Cancer Campus, Grand Paris. It is currently in Phase 3 development for Metastatic urothelial carcinoma, Metastatic non-small cell lung cancer, Soft tissue sarcoma.

Doxorubicin, ifosfamide, and cisplatin work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells.

Doxorubicin, ifosfamide, and cisplatin work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells. Used for Metastatic urothelial carcinoma, Metastatic non-small cell lung cancer, Soft tissue sarcoma.

At a glance

Generic namedoxorubicin, ifosfamide, cisplatin
SponsorGustave Roussy, Cancer Campus, Grand Paris
Drug classanthracycline antibiotic, alkylating agent, platinum-based alkylating agent
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Doxorubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and causing DNA damage. Ifosfamide is an alkylating agent that cross-links DNA, causing DNA damage and cell death. Cisplatin is a platinum-based alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about doxorubicin, ifosfamide, cisplatin

What is doxorubicin, ifosfamide, cisplatin?

doxorubicin, ifosfamide, cisplatin is a anthracycline antibiotic, alkylating agent, platinum-based alkylating agent drug developed by Gustave Roussy, Cancer Campus, Grand Paris, indicated for Metastatic urothelial carcinoma, Metastatic non-small cell lung cancer, Soft tissue sarcoma.

How does doxorubicin, ifosfamide, cisplatin work?

Doxorubicin, ifosfamide, and cisplatin work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells.

What is doxorubicin, ifosfamide, cisplatin used for?

doxorubicin, ifosfamide, cisplatin is indicated for Metastatic urothelial carcinoma, Metastatic non-small cell lung cancer, Soft tissue sarcoma.

Who makes doxorubicin, ifosfamide, cisplatin?

doxorubicin, ifosfamide, cisplatin is developed by Gustave Roussy, Cancer Campus, Grand Paris (see full Gustave Roussy, Cancer Campus, Grand Paris pipeline at /company/gustave-roussy-cancer-campus-grand-paris).

What drug class is doxorubicin, ifosfamide, cisplatin in?

doxorubicin, ifosfamide, cisplatin belongs to the anthracycline antibiotic, alkylating agent, platinum-based alkylating agent class. See all anthracycline antibiotic, alkylating agent, platinum-based alkylating agent drugs at /class/anthracycline-antibiotic-alkylating-agent-platinum-based-alkylating-agent.

What development phase is doxorubicin, ifosfamide, cisplatin in?

doxorubicin, ifosfamide, cisplatin is in Phase 3.

What are the side effects of doxorubicin, ifosfamide, cisplatin?

Common side effects of doxorubicin, ifosfamide, cisplatin include Myelosuppression, Nausea and vomiting, Neutropenia, Anemia, Thrombocytopenia.

Related